{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:32:55Z","timestamp":1793035975222,"version":"4.5.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Drug Delivery"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1080\/10717544.2021.1931559","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T10:43:17Z","timestamp":1623494597000},"page":"1132-1140","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":51,"title":["Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone\u00a0"],"prefix":"10.1080","volume":"28","author":[{"given":"Guanxing","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Oncology, Municipal Hospital of Zaozhuang, Zaozhuang, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Municipal Hospital of Zaozhuang, Zaozhuang, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Municipal Hospital of Zaozhuang, Zaozhuang, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,6,12]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26287"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2168"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S198003"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.054"},{"key":"e_1_3_2_6_1","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang SS","year":"1999","unstructured":"Chang SS, O\u2019Keefe DS, Bacich DJ, et\u00a0al. (1999). Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674\u201381.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10731191003685481"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.109988"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110181"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/nn301725w"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.5345"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S272495"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.01.041"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.10.066"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2020.1837294"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109225"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63112-4"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108614"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.206"},{"key":"e_1_3_2_21_1","first-page":"12","article-title":"High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer","volume":"5","author":"Ketola K","year":"2016","unstructured":"Ketola K, Viitala M, Kohonen P, et\u00a0al. (2016). High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. J Mol Biochem 5:12\u201322.","journal-title":"J Mol Biochem"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.12.027"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2019.1710622"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01436"},{"key":"e_1_3_2_25_1","first-page":"1255","article-title":"Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy","volume":"11","author":"Li N","year":"2019","unstructured":"Li N, Xie X, Hu Y, et\u00a0al. (2019). Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy. Am J Transl Res 11:1255\u201369.","journal-title":"Am J Transl Res"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.12.040"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S172199"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.02.001"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2019.1709922"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1146-03"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21149"},{"key":"e_1_3_2_32_1","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver DA","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, et\u00a0al. (1997). Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S211224"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.12.006"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S201722"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S184634"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111249"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S235098"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0422"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184459"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S182197"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S270303"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108820"},{"key":"e_1_3_2_44_1","first-page":"102","article-title":"Development, characterization and evaluation of doxorubicin nanostructured lipid carriers for prostate cancer","volume":"22","author":"Zhang HW","year":"2017","unstructured":"Zhang HW, Dang Q, Zhang ZW, Wu FS. (2017). Development, characterization and evaluation of doxorubicin nanostructured lipid carriers for prostate cancer. J BUON 22:102\u201311.","journal-title":"J BUON"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S211130"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S143047"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.10.158"},{"key":"e_1_3_2_48_1","first-page":"257","article-title":"Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer","volume":"10","author":"Zhao X","year":"2014","unstructured":"Zhao X, Chen Q, Liu W, et\u00a0al. (2014). Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Int J Nanomed 10:257\u201370.","journal-title":"Int J Nanomed"}],"container-title":["Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10717544.2021.1931559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T15:39:54Z","timestamp":1724168394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10717544.2021.1931559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1080\/10717544.2021.1931559"],"URL":"https:\/\/doi.org\/10.1080\/10717544.2021.1931559","relation":{},"ISSN":["1071-7544","1521-0464"],"issn-type":[{"value":"1071-7544","type":"print"},{"value":"1521-0464","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=idrd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=idrd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}